VR Logo

Inovio Pharmaceuticals Inc. (INO) download report


Healthcare | Biotechnology & Pharma Research

Inovio Pharmaceuticals Inc. (INO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

IPO Date: 12-Feb-1998

CEO, Pres & Director: Dr. Jacqueline E. Shea Ph.D.

Chief Financial Officer: Mr. Peter D. Kies

Listing: NASDAQ: INO

Country: United States

Headquarters: Plymouth Meeting, PA

Website: https://www.inovio.com

Key Facts

Market cap: $542.83 Mln

Revenue (TTM): $1.60 Mln

Earnings (TTM): $-328.33 Mln

Cash: $360.39 Mln

Total Debt: $33.65 Mln

Insider's Holding: 1.66%

Liquidity: Low

52 Week range: $1.38 - 9.96

Shares outstanding: 229,040,992

10 Years Aggregate:

  • CFO: $-770.80 Mln
  • EBITDA: $-914.30 Mln
  • Net Profit: $-999.35 Mln

Stock Performance

Time Period Inovio Pharmaceuticals (INO) S&P BSE Sensex* S&P Small-Cap 600*
YTD-52.511.05-11.58
1 month25.408.658.86
3 months-23.307.34-2.19
1 Year-72.958.45-6.23
3 Years-3.7717.079.73
5 Years-15.5012.777.72
10 Years1.5512.8310.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Inovio Pharmaceuticals (INO) S&P Small-Cap 600 S&P BSE Sensex
2021-43.6225.2721.99
2020168.189.5715.75
2019-17.5020.8614.38
2018-3.13-9.705.87
2017-39.1011.7327.91
20163.2724.741.95
2015-26.80-3.36-5.03